Drug Trial Radar · NCT07174492
Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients
Last checked: Nov 19, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
412
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- AB ScienceIndustry
- Sponsor type
- Industry
- First posted
- Sep 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Interventions
Masitinib 4.5 mg/kg/dayDrug
Masitinib (titration to 4.5 mg/kg/day)
PlaceboDrug
treatment per os
Riluzole (100 mg)Drug
Riluzole 50 mg tablet, treatment per os
Primary outcomes
What the sponsor says the trial is designed to measure.
- ALSFRS-RTime frame: 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aiginition Hospital
Athens, Greece
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.